Epidemiology of Hepatitis B in Ireland. by Murphy, Niamh & Thornton, Lelia
A worrying concentration of  Verotoxigenic E. coli (VTEC) notifications has been observed over recent
weeks in HSE-South. An earlier peak in May was accounted for by two family clusters. However, over half
of the region’s 25 VTEC notifications so far this year have occurred in the eight-week period since late
June (Fig 1). In that period, thirteen cases of VTEC (8 confirmed / 5 probable) - comprising 4 sporadic
cases and 3 family clusters - have been notified. All except two cases utilised a home drinking water
supply from a private well.
Investigators are concerned that
exposure to private well drinking water
may be a primary risk factor in most of
these June-Aug instances. A family VTEC
cluster of four cases, all symptomatic,
had a private well in use which was
found to be microbiologically
contaminated. VTEC O157 was isolated
from a sample of that well water. Wells
in two other instances were
microbiologically contaminated
although VTEC was not detected.
Results in other instances are pending.
Excessive rainfall this summer has resulted in unprecedented high water table levels, excessive runoff and
flooding. The potential for microbiological contamination of drinking water is increased. Private water
supplies have been repeatedly highlighted as a concern in relation to VTEC infection in Ireland (HPSC
Annual Reports 2004/5/6). There is a need for maximum vigilance in the surveillance of potentially
waterborne infections at this time.
MB O’ Sullivan, A Brennan. HSE-South (Cork & Kerry)
VTEC notifications nationally
have also risen in 2008, with
139 cases notified year-to-
date compared with
approximately 70-90 cases
reported in the equivalent
time periods of 2006-2007.
Most recently, this increase
has been most prominent in
the South and the South East.
So far this year, 30% of cases
are reported to have occurred
where private wells are in use.
While not all cases in private
well households are related to
water consumption, HPSC
strongly advises all private well owners to make sure that their wells are maintained appropriately.
In times of heavy rainfall users may need to consider boiling their water or taking other appropriate
measures particularly if vulnerable people such as children, the elderly or immunocompromised persons
are drinking the water and particularly if the householder notices a change in the character of the water
at such times e.g. colour/taste/odour. Further advice on private wells is available from both HSE
Environmental Health Service and local authorities.
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Fig 1. VTEC Notifications HSE-South (Cork & Kerry) 2008
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Introduction
Hepatitis B virus is a common cause of morbidity and mortality, with
more than 350 million people chronically infected worldwide.
Transmission of the virus is through contaminated blood and body
fluids and hepatitis B infection occurs mainly in well defined risk
groups such as babies born to infected mothers, sexual or household
contacts of infected people, injecting drug users (IDUs), heterosexuals
with multiple partners, and men who have sex with men (MSM).
Many cases, particulary adults, are asymptomatic in the acute phase.
There is a high probability of developing chronic infection if hepatitis
B is acquired in infancy or early childhood. Ninety percent of infants
infected at birth and 20-50% of children infected between one and
five years become chronically infected, compared to 1-10% of those
who acquire hepatitis B later in life. Approximately 15-40% of people
who are chronically infected will ultimately develop cirrhosis, liver
failure or hepatocellular carcinoma (HCC).1 
In countries of high endemicity, infection is usually acquired perinatally
or in early childhood.1 Ireland is a low endemicity country and most
cases acquired in Ireland are probably acquired sexually in early
adulthood when there is a high probability of clearing the virus. The
epidemiology of hepatitis B in Ireland has changed significantly in
recent years with changes in immigration patterns.
Methods
Sources of data for this report include statutory notifications to the
Health Protection Surveillance Centre (HPSC), prevalence studies and
screening programmes, the Department of Enterprise, Trade and
Employment (DETE), the Office of the Refugee Applications
Commissioner (ORAC), the Central Statistics Office (CSO), the Irish
Blood Transfusion Service (IBTS) and the National Cancer Registry of
Ireland (NCRI).
Results
Hepatitis B statutory notifications
The number of hepatitis B notifications to HPSC increased almost 30-
fold between 1997 (n=31) and 2007 (n=863) (figure 1).
Hepatitis B notifications, 2004 to 2007 
Improvements were made to the hepatitis B notification system in
January 2004 with the introduction of mandatory laboratory reporting
and the differentiation of acute and chronic cases. Between 2004 and
2007, 3,263 cases of hepatitis B were notified to HPSC. Acute/chronic
status was reported for 86% (n=2,819) and 90% of these were chronic
(n=2,545).
Acute cases 2004-2007
Seventy-seven percent (n=211) of the acute cases notified between
2004 and 2007 were male, 21.5% (n=59) were female and sex was
unknown for four cases.The highest notification rates were in young to
middle-aged adults, with 69% (n=189) of cases aged between 20 and
44 years (figure 2).
Where the reason for testing was known (n=195/274), 71% (n=138)
of acute cases notified between 2004 and 2007 were tested because
they were symptomatic. Risk factor information was available for 74%
(n=203/274). Of these, 57% (n=115) were likely to have been sexually
acquired and an additional 11% (n=23) were born in hepatitis B
endemic countries or were asylum seekers. Of the sexually acquired
cases, 56 were MSM, 50 were heterosexual and sexual orientation was
unknown for the remaining nine. Where country of birth was known
(n=185/274), 82% (n=151) of acute cases were born in Ireland.
Chronic cases, 2004-2007
The sex distribution of chronic cases was more even than that of acute
cases. Where sex was known, 54% (n=1,308) of chronic cases were
male and 46% (n=1,118) were female. The majority of chronic cases
were also young to middle-aged adults, with 82% (n=2,090) aged
between 20 and 44 years (figure 3).
Enhanced data were more limited for chronic cases. Where the reason
for testing was known (n=908/2,545), 41% (n=369) of chronic cases
were identified through voluntary health screening programmes for
asylum seekers and a further 29% (n=259) were diagnosed as a result
of antenatal screening programmes in maternity hospitals. Where
information on country of birth or asylum seeker status was available
(n=789/2,545), 90% (n=707) of chronic cases were either born in a
country where hepatitis B is endemic or were asylum seekers.
Hepatitis B prevalence data
The prevalence of hepatitis B infection in the general population in
Ireland is low. Serum hepatitis B surface antigen (HBsAg) is a marker
for current acute or chronic infection. Serological surveillance was
carried out in 2003 as part of the European Sero-Epidemiology
Network project and a HBsAg prevalence of 0.1% was found in the
Irish samples tested (ESEN-2 unpublished data). Blood donor screening
results also indicate a low prevalence in the general population. The
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Figure 1. Number of cases of hepatitis B notified, 1988 – 2007
*Laboratories required to notify HBV and acute/chronic status reported routinely from January
1st 2004
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Figure 2. Mean annual age- and sex-specific notification rates for acute
cases of hepatitis B, 2004-2007
IBTS tested 207,015 first time blood donors between 1997 and 2006
and found a HBsAg prevalence of 0.014% (personal communication
IBTS, February 2007).
However, hepatitis B is more prevalent in certain high-risk sub-groups
of the population such as people who have immigrated to Ireland
from intermediate (2-7% HBsAg prevalence) or high (≥8% HBsAg
prevalence) endemicity countries and IDUs. Thirty-five to forty
percent of all new asylum applicants are screened for communicable
disease in the HSE E. A review of the screening service in this area was
carried out in 2004 and found that of those tested for HBsAg between
1999 and 2003, 5% were positive.2 Routine antenatal testing for
HBsAg was introduced in the Rotunda in 1998. Uptake was almost
100% and 16,222 pregnancies were screened between January 1998
and June 2000. They found a HBsAg prevalence of 4.2% in non-EU
women and 0.03% in Irish women tested.3 
A cross-sectional study of 316 opiate users attending 21 addiction
treatment centres in the HSE E was carried out between December
2001 and January 2002 and found a HBsAg prevalence of 2% in this
population.4
Immigration data
The prevalence of hepatitis B in Ireland is influenced by the
immunisation policies and the prevalence of hepatitis B in the
country of birth of immigrants to Ireland.
Almost 60,000 (58,185) asylum applications were received by ORAC
between 2000 and 2007. Ninety-five percent of applicants were from
countries with intermediate or high hepatitis B endemicity. The
number of work permits issued by DETE has also increased
substantially in recent years, with 125,312 new permits issued
between 2000 and 2007. Seventy-two percent of recipients were
from countries of hepatitis B high or intermediate endemicity.
Hepatocellular carcinoma data
HCC is the most common form of primary liver cancer and the most
important causes worldwide are chronic infection with hepatitis B
and hepatitis C. Four hundred and four cases of HCC were registered
with the NCRI between 1994 and 2006. Seventy nine percent were
males and the average age was 66 years for males and 62 years for
females (personal communication: NCRI, July 2007).
The proportion of HCC cases that were due to hepatitis B is unknown.
However a systematic review of all published data on the prevalence
of hepatitis B and C infection among HCC cases found that of 4,308
European cases of HCC, 23.1% were positive for HBsAg and a further
6.5% were positive for both HBsAg and hepatitis C antibodies. One of
the studies included in this was set in the UK and found that of 80
cases of HCC, 16.3% were positive for HBsAg and 2.5% were positive
for both HBsAg and anti-hepatitis C antibodies.5 From these, we
would expect that between 19 and 30% of Irish HCC cases are
infected with hepatitis B.
The CSO reported an underlying cause of death of primary liver
cancer for 355 people between 1994 and 2006 (personal
communication: CSO, August 2008).
Discussion
The epidemiology of hepatitis B has changed significantly in Ireland in
recent years with changes in immigration patterns. Sexual exposure
has remained the predominant risk factor for acute cases but the vast
majority of cases being notified now are chronic cases. Most have
immigrated to Ireland, having contracted hepatitis in their countries
of birth.
These changes have implications for service provision as many of the
current carriers have probably been infected since infanthood or early
childhood and are at risk of developing liver failure, cirrhosis or
hepatocellular carcinoma. Without intervention, new babies born to
these parents are at high risk of becoming chronically infected
perinatally or horizontally through household contact.
Changes to hepatitis B prevention and control strategies have been
implemented. Hepatitis B is a vaccine-preventable disease and in
1992 the World Health Organization (WHO) recommended that the
hepatitis B vaccine be included in routine immunisation programmes
in all countries by 1997. The immunisation policy in Ireland has been
based on targeting people who fall into defined risk groups for
vaccination. This immunisation policy is set to change in September
2008 with the implementation of the Immunisation Guidelines for
Ireland (http://www.ndsc.ie/hpsc/A-Z/VaccinePreventable
/Vaccination/Guidance/). In addition to the current targeted
immunisation programme, all infants will be offered the hepatitis B
vaccine as part of the routine childhood immunisation schedule at 2,
4, and 6 months.
In addition, all Irish maternity hospitals now routinely carry out
antenatal screening for hepatitis B and follow up to babies born to
positive mothers. The HSE has also prepared information leaflets for
people with hepatitis B and their family members in several languages
(http ://www.ndsc . ie/hpsc/A-Z/Hepat it i sHIVAIDSandSTIs
/HepatitisB/Factsheets/).
These measures will go a long way towards preventing new hepatitis
B infections in infants and young children. However, additional work
must be done to ensure that adult risk groups are targeted effectively
and immunised.
Niamh Murphy, Lelia Thornton, HPSC
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Figure 3. Mean annual age- and sex- specific notification rates for chronic
cases of hepatitis B, 2004-2007
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Update on a multi-country outbreak of Salmonella Agona, February - August 2008
An outbreak of gastroenteritis affecting residents in Ireland, the United
Kingdom, Finland, France and Sweden is currently being investigated by an
international outbreak control team led by the Health Protection
Surveillance Centre in Ireland.
On 15th July the Health Protection Surveillance Centre was informed by
the National Salmonella Reference Laboratory (NSRL)  of an increase in S.
Agona isolates over the previous 3 weeks. Colleagues in United Kingdom
(UK) Surveillance Centres were informed on the 16th July and reported
that there was also a recent increase in isolates in the UK. Alerts were
posted through the Food and Waterborne Disease Network (European
Centre for Disease Control) and also the European Union (EU) Early
Warning and Response System (EWRS) on 23rd July.
Microbiological results
Microbiological investigations demonstrate S. Agona isolates with
indistinguishable PFGE profile SAGOXB.0066 in isolates from cases, and
food samples from a specific food producer. The specific strain of S. Agona
has been detected in a number of meat products from a food plant in
Ireland and in meat products collected from outlets supplied by the plant
in both Ireland and the United Kingdom. In addition, this strain of S. Agona
has been detected in environmental samples from the side of the plant
dealing with uncooked food.
Case definition
Confirmed: S. Agona with PFGE SAGOXB.0066 profile
Probable: S. Agona PT 39
Possible: S. Agona where PT unknown or PFGE profile unknown in Ireland
and the United Kingdom
To date, there are 144 cases in total meeting the above case definition. Of
these, 140 are PFGE confirmed cases with one probable and three possible
cases awaiting definitive analysis. The most recent date of onset reported
is 7th August 2008. Cases range in age from 3 months to 79 years with a
median age of 27 years. The majority of cases are in males i.e. 57% (M =
82 cases, F= 62 cases). To date, 19 cases (13%) are known to have been/are
currently hospitalised. There has been one death associated with the
outbreak.
Epidemiological studies
A case control study in Ireland (11 Irish cases with 33 matched controls)
has demonstrated a highly significant association between illness and
consumption of made to order sandwiches in outlets supplied by the
implicated company.
Control
The company concerned has ceased production on the implicated line since
August 1st and a recall of products from  this line has been put in place. As
it may take several weeks from onset of illness to the results of detailed
molecular analysis more cases fitting the case definition may be diagnosed
and the epidemiological situation continues to be monitored.
Darina O’Flanagan, Martin Cormican (NSRL) 
on behalf of the Outbreak Control Team.
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SUMMARY OF LABORATORY DATA TO DATE – HUMAN CASES
Table 1.Number of confirmed, probable, and possible S. Agona cases by countr
February 1st to August 25th 2008 
Country Feb Mar Apr May Jun Jul Aug Total
England 2 0 8 13 20 39 1 83
Finland 0 0 0 1 0 0 0 1
France 0 0 0 0 0 1 0 1
Ireland 0 0 0 0 2 8 1 11
N. Ireland 0 0 0 1 0 0 1 2
Scotland 0 0 0 4 13 13 4 34
Sweden 0 0 0 0 0 1 1 2
Wales 0 0 0 3 3 3 1 10
Total 2 0 8 22 38 65 9 144
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Figure 2: Reported number of confirmed, probable, and possible S. Agona cases
by age and gender . February 1st to August 25th 2008 at 15:00 (n=144)
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Figure 3: Reported number of confirmed, probable, and possible S. Agona
cases by date of onset and country
February 1st to August 25th 2008 at 15:00
Where the date of onset is unknown, the specimen  date or a calculated date (lab receipt date-
mean diff of lab receipt-onset) is used. Date of Onset unknown for n=26 cases.
Figure 1 Image of Pulsed
Field Gel Electrophoresis of 7
S. Agona isolates digested
with XbaI. Lanes 1, 5 and 10
are the S. Branderup control.
Lanes 2,3,4, 6, 8 and 9 are
the S. Agona SAGOXB.0066
strain from patients and
food sources. Lane 7
represents an unrelated S.
Agona isolate
